Introducing the IMED Biotech Unit What science can do Introduction What science can do
At AstraZeneca, our purpose is to push the Our IMED Biotech Unit applies its research and Our approach to R&D development capabilities and technologies to The IMED Biotech Unit plays a critical boundaries of science to deliver life-changing accelerate the progress of our pipeline. Through role in driving AstraZeneca’s success. Working together with MedImmune, medicines. We achieve this by placing science great collaboration across our three science units, our global biologics arm and Global we are confident that we can deliver the next wave Medicines Development (GMD), our at the centre of everything we do. late-stage development organisation, of innovative medicines to transform the lives of we are ensuring we deliver an innovative patients around the world. and sustainable pipeline.
Pancreatic beta cells at different Eosinophil prior to Minute pieces of circulating tumour DNA stages of regeneration apoptosis (ctDNA) in the bloodstream
IMED Biotech Unit MedImmune Global Medicines Development Focuses on driving scientific advances Focuses on biologics research and Focuses on late-stage development in small molecules, oligonucleotides and development in therapeutic proteins, of our innovative pipeline, transforming other emerging platforms to push the monoclonal antibodies and other next- exciting science into valued new boundaries of medical science. generation molecules to attack a range medicines and ensuring patients of diseases. around the world can access them.
It’s science that compels us to push the boundaries of what is possible. We trust in the potential of ideas and pursue them, alone and with others, until we have transformed the treatment of disease.
Nanoparticles circulating in the blood stream 02 What science can do Introducing the IMED Biotech Unit 03 Our IMED Biotech Unit This is an exciting time to be Oncology; Cardiovascular and part of the Innovative Medicines Metabolic Diseases (CVMD); and Early Development (IMED) and Respiratory, Inflammation Biotech Unit. Our IMED teams and Autoimmunity (RIA). By and their passion for science remaining committed to working We are committed to driving scientific advances mean that we are now seeing openly and collaboratively our breakthrough discoveries with the best people and the in small molecules, nucleotides and other translate into medicines which best partners we are confident emerging technology platforms to push the can improve the lives of patients that we can gain a new with serious diseases, for understanding of disease to boundaries of medical science. which current treatments are deliver life-changing medicines.” limited. We are fuelling a world- Mene Pangalos class AstraZeneca pipeline Executive Vice President IMED Biotech Unit and Global Business Development across our main therapy areas:
Each year we invest in excess of of science into drug discovery and $1 billion in discovering and developing ultimately innovative medicines. the next generation of life-changing We are pioneering new approaches medicines, from initial target selection to Open Innovation, creating a more through to the end of Phase II trials. permeable research environment where We employ over 2,300 scientists and our scientists can freely share their undertake research on a truly global ideas and know-how, and collaborate scale, operating vibrant science centres on projects with the very best academic across three continents. scientists. We remain committed to a Partnering and collaboration is a way culture of openness and will continue of life for our teams. We work alongside to identify innovative ways to connect scientists at many of the world’s leading the great science happening in our academic institutions to increase our laboratories with the best external understanding of disease physiology science from around the world. and help accelerate the translation
We believe in the potential of ground-breaking science to transform the lives of patients. We do this by focusing on three key priorities:
Fostering a culture where science Creating an environment open for Challenging conventional thinking, thrives, one that is dynamic, agile and innovation, where our teams work side we encourage our people to apply entrepreneurial by side with our academic and industry scientific rigour by challenging the way partners to make the next breakthrough we do things
CRISPR (clustered regularly interspaced palindromic repeats) gene editing tool
04 What science can do Introducing the IMED Biotech Unit 05 Where science thrives
We are achieving scientific leadership through a dynamic, agile and entrepreneurial culture that feels like a biotech but has the resources of a major global pharmaceutical company.
IMED Biotech Unit by numbers at end of 2016
Inspiring great scientists Delivering a step change Our commitment to scientific leadership in R&D productivity rests on our ability to attract and retain and output the best scientists. Nowhere is this commitment more evident than in the Since it was formed in 2010, the way we recruit, develop and inspire IMED Biotech Unit has helped deliver our people. We want to attract the sustainable improvements in R&D brightest minds, the best talent, the productivity across AstraZeneca. We >95% boldest innovators - people who share have improved our success rates from ~2,300 our passion for science and belief of IMED projects first time in human and successful people with a passion in the possible. In return, we offer a completion of Phase III from 3.5 per with Personalised working environment that truly reflects cent to over 15 per cent - a clear 40 for science our ambition to push the boundaries improvement over the current industry Healthcare approach high impact of science. A place where curiosity, average of four per cent. Even more innovation and collaboration flourish, importantly, this is translating into the publications in 2016 where drive and determination is delivery of new medicines, with drugs like rewarded and where great science olaparib, osimertinib and CAZ AVI having comes alive. graduated to a successful launch. We believe that great science comes Personalised Healthcare (PHC) is at the from diverse teams with different heart of our science based approach to backgrounds and the vision for our drug development. We have invested workforce is that it reflects the diversity heavily in the skills, partnerships and of our patient population. That’s why we technology to achieve this, with 95 per are committed to creating an inclusive cent of our small molecule pipeline and environment for our people. more than 80 per cent of our clinical ~1,000 pipeline now following a PHC approach. ongoing Building our scientific collaborations reputation We are entrepreneurs in science, pushing the boundaries of what’s $13.5M possible each and every day. That’s why we have cultivated an environment generated from Open of excellence together with a strong track-record of publications. Our $1 Innovation entrepreneurial spirit gives our scientists Over $1 billion invested the courage to take smart risks and 38% not be discouraged by failure. We in scientific research of women in senior empower our scientists to not only keep each year abreast of the latest developments and scientific roles breakthroughs, but to drive them.
06 What science can do Introducing the IMED Biotech Unit 07 We call this our Both our IMED Biotech Unit teams and 5R framework our Early Stage Portfolio Committee Focusing on quality (ESPC) use this framework to ensure we We have established a culture where are progressing the right projects, asking our teams are ‘truth seeking’ in their the right questions and making the right not quantity behaviour and rigorous in their approach decisions at key review points throughout to asking the critical ‘killer’ questions. the drug development process. Rather than being rewarded for hitting Lessons learned from the fate of AstraZeneca’s drug the next milestone, our scientists are pipeline: a five-dimensional framework Cook et al rewarded for thinking about what Nature Reviews Drug Discovery 13, 419–431 (2014) The 5R framework emphasises quality it would take to deliver a viable, differentiated medicine. rather than quantity in our R&D. That’s why a sixth critical factor is having the right culture.
Oncology tumour drivers – cell surface and lipid bilayer with receptor Our 5R framework
Right safety Differentiated and clear safety margins Right target Understanding Strong link between of secondary Right commercial target and disease pharmacology risk opportunity Understanding Differentiated Differentiated value efficacy of reactive metabolites, proposition versus Available and genotoxicity, drug- future standard of care predictive drug interactions Focus on market biomarker Understanding of access, payer and target liability provider Right tissue Personalised healthcare strategy, Adequate Right patients including diagnostics bioavailability and and biomarkers tissue exposure Identification of the most responsive Definition of PD patient population biomarkers Definition of risk- Clear understanding benefit for given of pre-clinical and population clinical PK/PD Understanding of drug-drug interactions
08 What science can do Introducing the IMED Biotech Unit 09 Neuroscience We also pursue opportunity driven Our therapeutic focus projects in Neuroscience. We have made a long-term commitment to neuroscience, with ongoing investment The future of treatment for many of today’s to deliver life-changing medicines to patients with neurodegenerative diseases, diseases lies in uncovering mechanisms that are chronic pain and addiction. Our business model thrives on being newly emerging or are still to be discovered. dynamic and partly externalised, with a laser-like focus driving science within our key areas of interest. Early, flexible partnering with the brightest and best in the world allows us to combine knowledge and progress clinical development, while managing the challenges associated with neuroscience research. We believe the best way to help patients is to focus on breakthrough science to discover these mechanisms and develop novel, targeted therapies that interact with them. Our focus in the IMED Biotech Unit is on the following three main therapy areas:
Oncology Respiratory, Inflammation Cardiovascular Our vision is clear. To help patients by and Autoimmunity & Metabolic Diseases redefining the cancer treatment paradigm and eliminating cancer as a cause of death. There are over 600 million people living We are committed to defining the new We aim to bring six new cancer medicines with asthma and chronic obstructive standard of care for the treatment of to patients between 2013 and 2020. pulmonary disease (COPD) around the heart failure, diabetes and chronic kidney world, with therapies limited to treating or disease (CKD). We have built knowledge Our broad pipeline of next-generation avoiding symptoms. and invested in key technologies to medicines is focused principally on four develop both our pipeline and our level disease areas: breast, ovarian, lung and Our robust portfolio of early targets of scientific expertise, coupling this with haematological cancers. We have one has the potential to transform the a patient-centric approach aimed at of the broadest and deepest pipelines in treatment of respiratory disease. We better understanding the interplay and the industry, spanning immuno-oncology, have revolutionised our respiratory potential causal relationship between DNA damage response (DDR) and strategy with a focus on three core these diseases, which often present in targeted therapies including cell death. themes: lung epithelium, lung immunity the same patient. This is opening up and lung regeneration. Increasing unprecedented opportunities for The practical delivery of personalised our understanding of disease drivers medicine remains critically important novel treatment paradigms to help forms the basis of our drug discovery in driving clinical benefit and the great strengthen our pipeline with further programme and supports our vision to majority of our current projects are differentiated drugs. deliver disease modifying medicines developing prospective patient that prevent, reverse or even cure these selection strategies. respiratory diseases.
10 What science can do Introducing the IMED Biotech Unit 11 Developing great scientists
We are driving diversity and inclusion to truly make the IMED Biotech Unit a great place to work. We believe that great science comes from diverse teams with different backgrounds and the vision for our workforce is that it reflects the diversity of our patient population.
Graduate programme Women as Leaders Chief Scientist programme Development Assignments During a two year programme, programme As part of our drive for the best science, graduates complete three placements Continuous development of our people we are committed to working with the across Innovative Medicines and Early is high on our agenda and the majority As part of creating a diverse workforce we best scientists both inside and outside Development, with a focus on breadth of our development comes from on-the- are committed to increasing the number the pharmaceutical industry. To ensure of experience. In addition to three job experience. From our Development of women in senior scientific roles. Since that we are able to attract top science placement line managers, graduates are Marketplace to cross-team secondments 2015 we have increased the number of talent from academia, we have developed supported by a mentor for the duration and shadowing opportunities, our women in senior scientific roles to 38 per our flexible Chief Scientist Programme. of the programme to offer career programmes ensure we continue cent and our aim is to further increase this By tailoring individual arrangements counselling and guidance. developing the skills and capabilities to going forward. to enable scientists to work with IMED equip our scientists to be the best they As well as developing technical skills Our ‘Women as Leaders’ programme Biotech Unit full time, part time, or can be. Throughout 2016, we saw more by working with world-class scientists gives our female scientists a chance to on assignment from a university, we than 60 colleagues take up assignments using state-of-the-art facilities, all come together to discuss issues such encourage a permeable research outside their core role to broaden their graduates are enrolled onto the Global as career progression and personal environment, meeting the needs of both learning and experience. Graduate Development Programme development, with a view to increasing the institution and individual. where the focus is on the softer skills their awareness of opportunities and the Being flexible in our approach enables that are required to make the successful confidence to pursue them. People that scientists of the highest calibre to transition into industry. have attended the programme have seen stay connected to their research, their My secondment in IMED a 30 per cent promotion rate and gained universities and to work flexibly between Communications has given sponsors, coaches and mentors. their commitments, while allowing us to me a great opportunity to connect with the best scientific minds to Thanks to the IMED discover and develop new medicines. learn new strategies, strengthen my network and graduate programme, I have We’ve made sure we have a push my boundaries. And gained experience from balanced recruitment process, Postdoctoral programme because it is a part time both IMED RIA and CVMD. we’ve trialled blind screening The postdoc programme brings assignment, I still get to do a Foremost, this has given me of CVs to remove unconscious together motivated and innovative job I love driving delivery for a comprehensive knowledge bias to gender. We also postdoc scientists who have a passion for great ideas and a desire to make Oncology clinical projects.” of drug development, but also employ diverse panels for all a difference through an academic a broad network of scientists. our interviews. This helps style postdoc position in a global Melinda Foulk, Drug Project This has proven to be very pharmaceutical setting. Information Manager, IMED us ensure we recruit the best Operations valuable and continuously person for the right role.” The two to three year programme funds provides me with new ideas”. postdoc projects originating from internal Amy Taylor, Associate Director, scientists/clinicians across the research Linn Strindhagen, IMED Graduate Strategic Planning and Operations, areas and scientific disciplines within Scientist ECD and Chairperson, Network of AstraZeneca. These projects address Women UK fundamental scientific challenges that underpin drug discovery and development. In addition, each postdoc scientist receives a tailored training and development programme encompassing key skills such as presentation delivery and publication writing.
12 What science can do Introducing the IMED Biotech Unit 13 Leadership through collaboration
Our teams are leading the way in creating an open research environment that goes beyond the usual collaboration models.
Large scale lab - rotating flask boiling off solvent to produce the drug product
We are always on the lookout for novel ways of working with others to We work flexibly with With research facilities in a number of the world’s advance medical science and speed up our partners in pursuit Partnering with the best established and emerging scientific centres, we delivery of new medicines to patients. of breakthrough science: academic and industrial We continue to build our network of � In-licensing new chemical innovative collaborations with academic scientists outside AstraZeneca modalities and platforms recognise the importance of leveraging our footprint institutions, biotech and pharmaceutical is critical. Combining our companies in our main therapy areas. � Sharing compounds to uncover strengths and resources with to connect with the best external science, accelerating Our pioneering work in genomics has novel target opportunities established a number of important the expertise and knowledge � Working side-by-side with our scientific partnerships and alliances with leading collaborations including, Human of our partners will ultimately external scientists to better Longevity, Wellcome Trust Sanger understand disease mechanisms benefit patients.” Institute, Stratified Medicines Scotland academic and biotech partners around our sites as sharing information, expertise Kumar Srinivasan, VP Scientific and the Institute for Molecular Medicine. and insight making our Partnering and Alliances, We have also forged partnerships on well as in other key locations across the globe. compounds available through IMED Biotech Unit rapidly-evolving technologies such as Open Innovation initiatives modified mRNA, epigenetic drivers, bicyclic peptides and innovations in personalised healthcare – driving Strengthening our focus scientific progress across on scientific leadership Our partners include: AstraZeneca has been our entire portfolio. � United Kingdom: Cancer Our Open Innovation partnerships with Research UK (CRUK) and the very bold in making things academic translational drug discovery Medical Research Council (MRC) available to academia, from centres and government-linked agencies include leading global scientific � United States: National talking to academia on 110 Institutes of Health (NIH) and the Sweden institutions, which help facilitate our their own terms, to learning 340 interactions with prominent scientists. National Center for Advancing from academia and gently UK Translational Research (NIH-NCATS) teaching us about themselves. 180 We feel we’re dealing with Europe � Taiwan: National Research 380 Program for Biopharmaceuticals colleagues.” US (NRPB) Sir Hugh Pelham, Medical Research Council 90 Laboratory of Molecular Biology, UK Asia � Singapore: National Health Pacific Innovation Centre (NHIC) � Australia: Universities of Queensland and Adelaide commercialisation units, UniQuest and Adelaide Research & Innovation
Active collaborations at end of 2016
14 What science can do Introducing the IMED Biotech Unit 15 Challenging convention Open Innovation
Our Open Innovation programme, designed to We are committed to ensuring that we contribute to create a permeable research environment where scientific advances that will benefit patients. One of scientists both inside and outside AstraZeneca the ways we do this is through Open Innovation and can more freely share their ideas and collaborate externalisation. on projects, has achieved great success.
Our Scientific Partnering and Alliances Our Open Innovation portal makes it Scientist examining a human placenta (SP&A) team work to strengthen our double stained using two different easy for external scientists to access Since its launch in 2014, our global partnerships with leading fluorescent antibodies and a nuclear our full range of Open Innovation Open Innovation programme has scientists from academia, biotech and counterstain by confocal microscopy programmes and find ways to advance established a proven track record of pharma and seek opportunities to medical science together: success: license our products. � A compound bank of ‘patient-ready’ Received over 400 proposals from In Respiratory during 2016, we announced active and discontinued compounds scientists in 28 countries across four a key licensing agreement with our � A pharmacology toolbox continents partner Insmed for the global exclusive of compounds with strong rights to AZD7986, a novel oral inhibitor of Formed 150 new partnerships, 90 pharmacological properties dipeptidyl peptidase I (DPP1). AZD7986 per cent with academic scientists may decrease the damaging effects of � A collaborative effort to validate new and 10 per cent with science inflammatory diseases, such as non-cystic targets, which may include high- companies fibrosis bronchiectasis, by inhibiting DPP1 throughput screening More than 150 pre-clinical and 30 and its activation of NSPs. � Advanced cheminformatic capabilities clinical studies initiated or planned, to explore therapeutic potential of new with our partners molecules openinnovation.astrazeneca.com � R&D challenges open to anyone willing to offer innovative solutions.
16 What science can do Introducing the IMED Biotech Unit 17 Preparing for the future with our IMED Futures teams
Delivering the next wave of life-changing medicines requires a new way of thinking. To ensure the IMED Biotech Unit remains at the cutting-edge of scientific innovation, we established our IMED Futures programme.
Preclinical Biosensors iDecide Digital IMED To enhance the impact of current online iDecide is a clinical informatics The wealth of ‘big data’ in healthcare data monitoring, our teams have been research and development framework is revolutionising our approach to exploring the possibilities within the enabling early and better decision- research and development. We are rich data source provided by sensor making in clinical studies. In already seeing how the next generation technology and wearable devices. collaboration with the Manchester of medicines are being shaped by Incorporating biosensor technology Cancer Research Centre (MCRC), our ability to capture, interpret and into our pre-clinical studies will allow iDecide is designed to integrate, apply data. Combining insight from us to change current practice, improve maintain and assess data during clinical health records with large-scale translation and safety read-outs, while an ongoing study utilising real time genomics data is enabling scientists to reducing the number of animal studies. feedback from patients. Leveraging better predict disease outcomes in the this patient-centric information in a clinic. Our team has been investigating Current technology allows measuring timely manner enables appropriate the possibility to connect multiple data the body’s vital signs using health adjustment to clinical trial design, stacks from anywhere and of any type, patches but our team recognises the saving resources and time while helping from proprietary data to real world true value for pre-clinical monitoring us investigate the right dose, of the evidence, even social media platforms. lies with invasive biosensor technology. right drug to the right patient. This data stack would truly allow us Advanced Drug Delivery iLead in Lead Generation In the future, developing pre-clinical to map 360 degree views of patient Microphysiological systems sensors that monitor drug exposure Improved understanding of the Focused on creating a capability that journeys and gain understanding of the - biochip with cellular matter and biomarkers of safety and efficacy physiological barriers to efficient drug enables our scientists to follow the interplay between ‘nature’ (from genetic will have the potential for clinical use – delivery has resulted in significant science and work on any therapeutic information) and ‘nurture’ (environmental providing online biosensors for patients, advances in delivery systems. This, target mechanism irrespective of data e.g. smartphone/sensor data) to and hence changing the status quo for coupled with novel analytical and its tractability. We aim to make make breakthroughs in science and patient care. imaging techniques allow for even more ‘undruggable’ targets ‘druggable’ by ultimately patient care. sophisticated delivery systems opening developing strategies that explore up new target space. Our team is next-generation approaches to small looking to improve efficacy by enhancing molecule hit identification and the our targeting capabilities to allow application of peptides and cyclic delivery of both small molecules and peptides as novel therapeutic modalities. oligonucleotide therapeutics – miRNA, mRNA and antisense. Organs on a Chip To do this our team is focused on cellular Microphysiological systems (MPS) targeting, improving cellular uptake are miniaturised models that combine and enhancing drug delivery, and other engineering and biology to generate new modalities. In the latter case, we organ function in vitro to emulate human have a co-exclusive license with Pfizer biology at the smallest acceptable for access to the BIND Therapeutics scale. MPS models enable scientists to ACCURINS® polymeric nanoparticle link organs together and discover key technology and with Starpharma for factors involved in organ cross-talk that exploring their dendrimer technology drive particular disease phenotypes – platform. Both these technologies can generating data with a high likelihood improve therapeutic index and ability to of clinical translation and offering a real formulate challenging molecules. alternative to the use of animals in drug discovery. Our team is collaborating with some of the leading experts in the world at TissUse, Emulate, Harvard and Vanderbilt Universities.
18 What science can do Introducing the IMED Biotech Unit 19 Our people, Key skills and skills and values capabilities in the IMED Biotech Unit In pushing the boundaries of science, we continue to harness our unique mix of scientific skills and capabilities, by providing our people with the tools they need to deliver industry-leading R&D performance.
We know that we need people with a Translational science and biology Clinical development Pharmaceutical Sciences Our people make us stand out burning passion for what science can do. Our translational expertise enables us Our Early Clinical Development team Pharmaceutical Sciences ensures and our values define us. When you visit an IMED Biotech Unit site, to accelerate the development of new designs and delivers development we implement intelligent design of you will meet people who are inspired by ‘druggable’ targets in human disease strategies and clinical studies that build medicines and delivery systems. science and its capacity to transform the We follow the science and select the right patients in early the credentials of novel targets. The By focusing on three priority areas, lives of patients. You will notice the pride We put patients first clinical trials. By analysing disease tissue place where our science meets the Early Chemical Development, Early our people have in what we’ve achieved; and applying bioinformatics approaches patient, our early clinical development Product Development and Advanced the breakthroughs we’ve made, the We play to win we are able to support the identification determines whether a promising Drug Delivery, the team supports medicines we’ve developed and the lives and validation of targets regulating compound is good enough to progress formulation and delivery for our portfolio we’ve helped to transform. Our people We do the right thing biological processes. Our Early Clinical to the large Phase III trials that inform across the main therapy areas, from are passionate about their work. They Development team specialises in final regulatory approval decisions and early discovery to Phase IIb clinical are also creative and entrepreneurial We are entrepreneurial interpreting quantitative data using the ultimately whether patients can begin trials. The group is closely involved with with a relentless drive to translate the latest model based drug development accessing a new treatment. project teams to influence the design of great science happening in our labs techniques and technologies. new molecules and early clinical trials into the next generation of medicines to Discovery sciences and specialise in cutting-edge drug transform disease. delivery system technology to support Our leading High Throughput Screening Personalised healthcare our ever expanding drug platforms We continue to welcome more talented capabilities ensure we can develop As a leader in personalised healthcare, colleagues to our team, including and deliver novel reagents and high and modalities. we are committed to matching new accomplished scientists, respected quality assays to support efficient and medicines to the patients most in academics and new graduates. effective pre-clinical drug discovery need. We combine industry-leading They come for many reasons – the and biomarker development in later commitment to great science, the expertise in companion diagnostics clinical phases. In parallel to this, we opportunity for personal development, with laboratory science in molecular use our screening capabilities to provide the open culture, the inspiring values, diagnostics, tissue diagnostics, imaging project teams with mechanism of action, the chance to be part of something and protein biomarkers, working biology, safety and drug metabolism life-changing. Whatever the reason, they collaboratively with our external partners and pharmacokinetics (DMPK) insights have joined a truly great place to work. to harness break-through technologies across lead generation and lead across the life-cycle of our medicines. optimisation projects, while our structure Interested in joining the IMED and biophysics group use protein Biotech Unit? Medicinal Chemistry structure and biophysics to understand Go to AZ.com and select careers the relationships between target protein Our medicinal chemistry capabilities and chemical space. enable us to integrate structural, pharmacological, pharmacokinetic and toxicological information to support Drug safety and metabolism the innovative design of novel chemical By following the science and combining compounds. Pushing the boundaries of our expertise with that of our external medicinal chemistry enables the delivery partners, we apply our drug metabolism of new candidate drugs into our pipeline and pharmacokinetics (DMPK) expertise and is the foundation of small molecule with discovery safety capabilities drug discovery across the company. We to ensure our teams accelerate the also work on next-generation devices discovery and development of safe and delivery through our pharmaceutical new medicines across our focus areas. development group.
20 What science can do Introducing the IMED Biotech Unit 21 Our thriving Creating science centres vibrant Biohubs
Our BioHubs offer an A bold R&D initiative to foster life sciences discovery and the exchange of ideas between scientists, our Boston energising environment BioHub, along with the BioVentureHub at the Gothenburg site in Sweden enabling cross-fertilisation and the BioHub at our Alderley Park site in the UK, all have vibrant but of ideas. distinctive features offering an energising environment, all about sharing ideas and tapping into great science.
CGI image of our new Global R&D Centre, Cambridge UK
UK – Cambridge UK – Macclesfield Sweden – Gothenburg In 2013, AstraZeneca announced plans Our Macclesfield site is an important hub Our strategic R&D centre in Gothenburg to move its UK research activities to a for AstraZeneca and the second largest is the centre of our research for two new $500 million facility in the centre pharmaceutical manufacturing site in of our main therapy areas; CVMD and IMED Biotech Unit of Cambridge. Our new facility at the the world. RIA. It is also home to a large number Cambridge Biomedical Campus will of our scientists from our early phase A centre of innovation, science and high- What science can do become AstraZeneca’s largest centre for tech manufacturing, it’s a place where Discovery Sciences function and our Oncology research, as well as hosting molecules are turned into medicines and Drug Safety and Metabolism (DSM) scientists focused on Cardiovascular and is home to the Pharmaceutical Sciences team. In addition to this we have teams Metabolic Diseases (CVMD); Respiratory, team, which joined the IMED Biotech Unit from IMED Operations, Scientific Inflammation and Autoimmune Diseases in 2016. With large-scale lab facilities, Partnering & Alliances, Early Clinical (RIA); and conditions of the central the site hosts cutting-edge technology to Development (ECD) and Personalised nervous system. enable intelligent design of medicines and Healthcare and Biomarkers (PHB). During 2016 we also welcomed a new AstraZeneca’s registered address has delivery systems. function, Pharmaceutical Sciences. now moved to the Cambridge Biomedical Seven miles away at Alderley Park, Campus, 1 Francis Crick Avenue, which now owned by Manchester Science marks a key point in delivering our Partnerships, we retain a small number China – Shanghai science-led strategy. The construction of IMED scientists until the R&D exit of Our small molecule research facility of the new R&D centre and corporate the site is complete and colleagues join in China is located at the Zhangjiang headquarters continues and the growing together in our new Cambridge facility. High Tech Park in the Pudong area of Campus will successfully create an Shanghai. Our research teams here optimum environment for emerging focus on discovering potential new businesses to thrive. US – Boston medicines that meet the unique needs Boston is home to AstraZeneca’s small of patients in Asia and drive forward
molecule research in North America, translational science across our main with state-of-the-art laboratories, just therapy areas. west of the city centre. Our scientists focus on the discovery and development of new medicines for Oncology and conditions of the central nervous system,
in collaboration with other functions from AstraZeneca’s Strategic across IMED. R&D Centre in Gothenburg
22 What science can do astrazeneca.com antiMRNA